Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with generalised myasthenia gravis (gMG).

The FDA has accepted the New Drug Application (NDA) for investigational, first-in-class oral antibiotic gepotidacin, according to a press release from manufacturer GSK. The drug, which has a n...

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers ...

An Eli Lilly executive has said the company will “build a new way of doing science” as part of its £279m ($363m) pledge to boost the UK’s life science sector.  A memorandum of...